SEC Form 4 · accession 0001182489-18-000381
MEDICINES CO /DE · MDCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clive Meanwell
Officer — CEO · Director
Period of report
Aug 31, 2018
Accepted (ET)
Sep 5, 2018 · 6:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113481
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2018 | A | 375 | $28.28 | A | 352,409 | D | |
| Common StockF3 | Sep 4, 2018 | S | 50,000 | $39.31 | D | 302,409 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares of common stock acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2018 and ending August 31, 2018. In accordance with the terms of the ESPP, these share were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 1, 2018.
- F2Sales were effected pursuant to a Rule 10b5-1 program adopted by Dr. Meanwell. Dr. Meanwell's 10b5-1 program is terminated.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $39.03 to a high of $39.77 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.